Aberrant DOCK2, GRASP, HIF3A and PKFP Hypermethylation has Potential as a Prognostic Biomarker for Prostate Cancer
Authors:
- Marianne T. BjerreMBMarianne T. Bjerre
- Siri H. StrandSSSiri H. Strand
- Maibritt NørgaardMNMaibritt Nørgaard
- Helle KristensenHKHelle Kristensen
- Anne Ki RasmussenARAnne Ki Rasmussen
- Martin Mørck MortensenMMMartin Mørck Mortensen
- Jacob FredsøeJFJacob Fredsøe
- Peter MouritzenPMPeter Mouritzen
- Benedicte UlhøiBUBenedicte Ulhøi
- Torben ØrntoftTØTorben Ørntoft
- Michael BorreMBMichael Borre
- Karina D. SørensenKSKarina D. Sørensen
Open Access
- 7 March 2019
- journal article
- research article
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 20 (5) , 1173
Abstract
Prostate cancer (PCa) is a clinically heterogeneous disease and currently, accurate diagnostic and prognostic molecular biomarkers are lacking. This study aimed to identify novel DNA hypermethylation markers for PCa with future potential for blood-based testing. Accordingly, to search for genes specifically hypermethylated in PCa tissue samples and not in blood cells or other cancer tissue types, we performed a systematic analysis of genome-wide DNA methylation data (Infinium 450K array) available in the Marmal-aid database for 4072 malignant/normal tissue samples of various types. We identified eight top candidate markers (cg12799885, DOCK2, FBXO30, GRASP, HIF3A, MOB3B, PFKP, and TPM4) that were specifically hypermethylated in PCa tissue samples and hypomethylated in other benign and malignant tissue types, including in peripheral blood cells. Potential as diagnostic and prognostic biomarkers was further assessed by the quantitative methylation specific PCR (qMSP) analysis of 37 nonmalignant and 197 PCa tissue samples from an independent population. Here, all eight hypermethylated candidates showed high sensitivity (75–94%) and specificity (84–100%) for PCa. Furthermore, DOCK2, GRASP, HIF3A and PKFP hypermethylation was significantly associated with biochemical recurrence (BCR) after radical prostatectomy (RP; 197 patients), independent of the routine clinicopathological variables. DOCK2 is the most promising single candidate marker (hazard ratio (HR) (95% confidence interval (CI)): 1.96 (1.24–3.10), adjusted p = 0.016; multivariate cox regression). Further validation studies are warranted and should investigate the potential value of these hypermethylation candidate markers for blood-based testing also.Keywords
Funding Information
- Dansk Kræftforsknings Fond (DKF-2016-66 - (25))
- Kræftens Bekæmpelse (R99-A6338-14-S25)
- Højteknologifonden (2012)
- Velux Fonden (11307)
This publication has 46 references indexed in Scilit:
- Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burdenGenome Medicine, 2017
- EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part 1: Screening, Diagnosis, and Local Treatment with Curative IntentEuropean Urology, 2017
- The ABC model of prostate cancer: A conceptual framework for the design and interpretation of prognostic studiesCancer, 2017
- What is the optimal definition of misclassification in patients with very low-risk prostate cancer eligible for active surveillance? Results from a multi-institutional seriesUrologic Oncology: Seminars and Original Investigations, 2015
- Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012International Journal of Cancer, 2014
- Active surveillance for clinically localized prostate cancer––A systematic reviewJournal of Surgical Oncology, 2014
- Cancer incidence and mortality patterns in Europe: Estimates for 40 countries in 2012European Journal of Cancer, 2013
- Time Trends and Local Variation in Primary Treatment of Localized Prostate CancerJournal of Clinical Oncology, 2010
- Prostate-Specific–Antigen Testing for Early Diagnosis of Prostate CancerNew England Journal of Medicine, 2001
- Biochemical Outcome After Radical Prostatectomy, External Beam Radiation Therapy, or Interstitial Radiation Therapy for Clinically Localized Prostate CancerJAMA, 1998